Paras Abbas, Oncologist at Aga Khan Medical Center, shared a post on LinkedIn:
“ESMO 2026: immunotherapy is now part of curative treatment for localized oesophageal and gastric cancer.
OSCC: CROSS → surgery → adjuvant nivolumab if residual disease.
Gastric/GEJ: perioperative D-FLOT plus durvalumab maintenance.
The algorithm has changed.”
You can also read: 10 Gastroesophageal Cancer Trials to Watch at ESMO 2026
